Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PLRX | US
0.62
5.68%
Healthcare
Biotechnology
30/06/2024
04/10/2024
11.53
11.31
12.00
11.26
Pliant Therapeutics Inc. a clinical stage biopharmaceutical company discovers develops and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474 a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095 a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics Inc. was incorporated in 2015 and is based in South San Francisco California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
61.7%1 month
55.3%3 months
55.9%6 months
53.0%-
-
1.75
0.15
0.12
-2.54
1.38K
-
-205.71M
701.04M
701.04M
-
-
-
-100.00
-40.06
26.09
12.26
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.35
Range1M
3.42
Range3M
4.58
Rel. volume
0.67
Price X volume
2.85M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Capricor Therapeutics Inc | CAPR | Biotechnology | 21.65 | 765.05M | 31.05% | n/a | 45.32% |
TNGX | TNGX | Biotechnology | 6.98 | 747.87M | -0.85% | n/a | 15.28% |
Opthea Limited | OPT | Biotechnology | 4.48 | 746.87M | -2.61% | n/a | -264.65% |
AbCellera Biologics Inc | ABCL | Biotechnology | 2.5 | 736.66M | 0.81% | n/a | 6.49% |
Arbutus Biopharma Corporation | ABUS | Biotechnology | 3.84 | 724.92M | -1.54% | n/a | 6.09% |
Erasca Inc. Common Stock | ERAS | Biotechnology | 2.54 | 717.56M | 0.79% | n/a | 11.96% |
Terns Pharmaceuticals Inc. | TERN | Biotechnology | 8.27 | 698.29M | 0.85% | n/a | 0.11% |
Mineralys Therapeutics Inc. | MLYS | Biotechnology | 13.88 | 690.21M | 8.44% | n/a | 0.00% |
CureVac N.V | CVAC | Biotechnology | 3.02 | 679.69M | 0.67% | n/a | 10.37% |
Avid Bioservices Inc | CDMO | Biotechnology | 10.63 | 678.14M | -1.02% | n/a | 353.77% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.54 | 0.76 | Cheaper |
Ent. to Revenue | 1,376.69 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 1.75 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 55.87 | 74.67 | Lower Risk |
Debt to Equity | 0.15 | -1.82 | Expensive |
Debt to Assets | 0.12 | 0.26 | Cheaper |
Market Cap | 701.04M | 3.73B | Emerging |